References
  1. Barkholt L,, Voltz-Girolt C, Raine J, Salmonson T, Schüssler-Lenz (2018) European regulatory experience with advanced therapy medicinal products. Nature Reviews/Drug Discovery
  2. Broichhausen C, Riquelme P, Ahrens N, Wege AK, Koehl GE, Schlitt HJ, Banas B, Fändrich F, Geissler EK, Hutchonson JA (2014) In question: the scientific value of preclinical safet pharmacology and toxicology studies with cell-based therapies. Molecular Therapy-Methods&Clinical Development 1, 14026: doi:10.1038/mtm.2014.26
  3. Van den Hoorn T, Nakchedi T, de Wolf ACMT, Pasmooij AMG, Van der Laan JW, Herberts CA. Mining Scientific Advices on cellular therapeutics, insight in the nonclinical development program. (in this issue)
  4. Sato Y, Bando H, Di Piazza M, Gowing G, Herberts CA, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW, Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider. Cytotherapy, 2019, 21: 1095-1111;https://doi.org/10.1016/j.jcyt.2019.10.001)
  5. Bradley AE, Black L. Evaluation of Stem Cell-Derived Cellular Therapy Products. Toxicological Pathology 2020, 1-6, DOI:10.1177/019262331|9897898.